Breast Cancer

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.

Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

Does "think pink" actually raise awareness of breast cancer?

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer and the progress of a promising fourth agent, T-DM1.

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

Combining tamoxifen with everolimus increased the clinical benefit rate, time to progression, and overall survival versus tamoxifen alone in postmenopausal women with metastatic breast cancer.

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Agustin A. Garcia, MD, from Keck School of Medicine of USC, discusses clinical trials that investigated combination therapy for treating advanced breast cancer.

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

In this interview, Lance A. Liotta, MD, PhD, discusses the hypothosis that led to the study and the research thus far into chloroquine.

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Patients with early-stage breast cancer at high risk of residual nodal disease might benefit from axillary lymph node dissection.